New 'Double Punch' cell therapy targets tough blood cancers
NCT ID NCT07519187
First seen Apr 16, 2026 · Last updated Jun 23, 2026 · Updated 14 times
Summary
This early-phase trial tests a new cell therapy called CAR 70-BCMA CAR-T for people with relapsed or refractory plasma cell neoplasms, a type of blood cancer. The therapy uses a patient's own immune cells, modified to attack two targets (CD70 and BCMA) on cancer cells. The study aims to check safety and find the right dose in 20 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
General Hospital of Western Theater Command of PLA
RECRUITINGChengdu, Chengdu, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CAR 70-BCMA dual-target CAR-T cells
What this could lead to
If it works, this could offer a new treatment option for patients with hard-to-treat plasma cell cancers that have stopped responding to other therapies.
What could go wrong
This is a very early, small trial (20 people) focused on safety. The therapy may not work or could cause serious side effects. It is not a cure, and long-term benefits are unknown.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.